S Bisdas1, U Smrdel2, F F Bajrovic3, K Surlan-Popovic4. 1. Department of Neuroradiology, Eberhard Karls University, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany. Sotirios.Bisdas@med.uni-tuebingen.de. 2. Department of Radiation Therapy, Oncology Institute Ljubljana, Zaloska 2, 1000, Ljubljana, Slovenia. 3. Department of Neurology, University Medical Center, Zaloska 7, 1000, Ljubljana, Slovenia. 4. Department of Neuroradiology, University Medical Center, Zaloska 7, 1000, Ljubljana, Slovenia.
Abstract
PURPOSE: The efficacy of concomitant chemoradiation in patients with glioblastomas (GBMs) cannot be reliably assessed until several weeks after therapy completion. Our aim was to evaluate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as an early predictive assay for the progression-free-survival. METHODS AND MATERIALS: A total of 22 patients with primary GBMs underwent DCE-MRI before, during and after completion of adjuvant chemoradiation. K (trans) (transfer constant between the intravascular and extravascular, extracellular space), v(e) (extracellular, extravascular volume) and IAUGC (initial area under the gadolinium concentration time curve) and their changes into treatment were assessed as prognostic markers (12 months of progression-free-survival (PFS)). RESULTS: Both responders (7 subjects) and non-responders (15 subjects) experienced a reduction in the baseline IAUGC and v(e) values during the early phase of the treatment. This reduction was more prominent in the responders and was statistically significant for the v(e) (P = 0.04). Baseline K (trans) values among responders demonstrated statistically significant reduction during the early phase of treatment (P = 0.001). Multivariate Cox regression analysis demonstrated significant relationship between response and the early changes in K (trans) values during the treatment (P = 0.04). Trend to significant prognostic value demonstrated the baseline K (trans), v(e) and IAUGC as well as the changes of IAUGC and K (trans) upon therapy completion. CONCLUSIONS: Early perfusion changes during concomitant chemoradiation in GBMs can be detected by means of DCE-MRI and have significant prognostic value for the 12-month PFS.
PURPOSE: The efficacy of concomitant chemoradiation in patients with glioblastomas (GBMs) cannot be reliably assessed until several weeks after therapy completion. Our aim was to evaluate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as an early predictive assay for the progression-free-survival. METHODS AND MATERIALS: A total of 22 patients with primary GBMs underwent DCE-MRI before, during and after completion of adjuvant chemoradiation. K (trans) (transfer constant between the intravascular and extravascular, extracellular space), v(e) (extracellular, extravascular volume) and IAUGC (initial area under the gadolinium concentration time curve) and their changes into treatment were assessed as prognostic markers (12 months of progression-free-survival (PFS)). RESULTS: Both responders (7 subjects) and non-responders (15 subjects) experienced a reduction in the baseline IAUGC and v(e) values during the early phase of the treatment. This reduction was more prominent in the responders and was statistically significant for the v(e) (P = 0.04). Baseline K (trans) values among responders demonstrated statistically significant reduction during the early phase of treatment (P = 0.001). Multivariate Cox regression analysis demonstrated significant relationship between response and the early changes in K (trans) values during the treatment (P = 0.04). Trend to significant prognostic value demonstrated the baseline K (trans), v(e) and IAUGC as well as the changes of IAUGC and K (trans) upon therapy completion. CONCLUSIONS: Early perfusion changes during concomitant chemoradiation in GBMs can be detected by means of DCE-MRI and have significant prognostic value for the 12-month PFS.
Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Martin D Pickles; Martin Lowry; David J Manton; Peter Gibbs; Lindsay W Turnbull Journal: Breast Cancer Res Treat Date: 2005-05 Impact factor: 4.872
Authors: Craig J Galbán; Thomas L Chenevert; Charles R Meyer; Christina Tsien; Theodore S Lawrence; Daniel A Hamstra; Larry Junck; Pia C Sundgren; Timothy D Johnson; Stefanie Galbán; Judith S Sebolt-Leopold; Alnawaz Rehemtulla; Brian D Ross Journal: Clin Cancer Res Date: 2011-04-28 Impact factor: 12.531
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Kathleen R Lamborn; W K Alfred Yung; Susan M Chang; Patrick Y Wen; Timothy F Cloughesy; Lisa M DeAngelis; H Ian Robins; Frank S Lieberman; Howard A Fine; Karen L Fink; Larry Junck; Lauren Abrey; Mark R Gilbert; Minesh Mehta; John G Kuhn; Kenneth D Aldape; Janelle Hibberts; Pamela M Peterson; Michael D Prados Journal: Neuro Oncol Date: 2008-03-04 Impact factor: 12.300
Authors: I Hwang; S H Choi; C-K Park; T M Kim; S-H Park; J K Won; I H Kim; S-T Lee; R-E Yoo; K M Kang; T J Yun; J-H Kim; C-H Sohn Journal: AJNR Am J Neuroradiol Date: 2019-12-05 Impact factor: 3.825
Authors: William A Hall; Eric S Paulson; Uulke A van der Heide; Clifton D Fuller; B W Raaymakers; Jan J W Lagendijk; X Allen Li; David A Jaffray; Laura A Dawson; Beth Erickson; Marcel Verheij; Kevin J Harrington; Arjun Sahgal; Percy Lee; Parag J Parikh; Michael F Bassetti; Clifford G Robinson; Bruce D Minsky; Ananya Choudhury; Robert J H A Tersteeg; Christopher J Schultz Journal: Eur J Cancer Date: 2019-10-12 Impact factor: 9.162
Authors: K Ina Ly; Bella Vakulenko-Lagun; Kyrre E Emblem; Yangming Ou; Xiao Da; Rebecca A Betensky; Jayashree Kalpathy-Cramer; Dan G Duda; Rakesh K Jain; Andrew S Chi; Scott R Plotkin; Tracy T Batchelor; Gregory Sorensen; Bruce R Rosen; Elizabeth R Gerstner Journal: Sci Rep Date: 2018-11-20 Impact factor: 4.379
Authors: Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra Journal: Cancers (Basel) Date: 2022-03-05 Impact factor: 6.639
Authors: Kavi Fatania; Russell Frood; Marcus Tyyger; Garry McDermott; Sharon Fernandez; Gary C Shaw; Marjorie Boissinot; Daniela Salvatore; Luisa Ottobrini; Irvin Teh; John Wright; Marc A Bailey; Joanna Koch-Paszkowski; Jurgen E Schneider; David L Buckley; Louise Murray; Andrew Scarsbrook; Susan C Short; Stuart Currie Journal: Cancers (Basel) Date: 2022-07-18 Impact factor: 6.575
Authors: Sun Won Park; Seung Hong Choi; Yeonah Kang; Eun Kyoung Hong; Jung Hyo Rhim; Roh Eul Yoo; Koung Mi Kang; Tae Jin Yun; Ji Hoon Kim; Chul Ho Sohn Journal: Korean J Radiol Date: 2020-06 Impact factor: 3.500